drugset / Trial / NCT04518982
Sintilimab and Lenalidomide as a Treatment for CAEBV
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is a multi-center, prospective, randomized, controlled clinical study to evaluate the effectiveness of a combination regimen of Sintilimab and lenalidomide in patients with chronic active EBV infection.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2021-08-01
- Completion
- 2021-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |